可使生物降解的长效制剂微胶囊技术是一种药物控释技术。在授控的较长的一段时间药物缓慢释放。在过去的二十年中，武田公司已经完善了其专有技术，即具有微胶囊的长效制剂，能在人体的6个多月保持血药浓度。武田希望能有一种技术，即在确定的治疗药物，使用缓释长效制剂微胶囊技术能在任何人体组织上定向使用。具体如下：{https://www.innocentive.com/ar/challenge/9933674}
AWARD: varies | DEADLINE: 1/26/15 | ACTIVE SOLVERS: 28 | POSTED: 12/10/14
Depot formulation using a biodegradable microcapsule is one technique for the controlled delivery of pharmaceuticals. The drug is slowly released over an extended period of time in a controlled manner. During the past two decades, Takeda has perfected its proprietary technology, which features a microcapsule depot formulation that maintains drug plasma levels for more than 6 months in humans. Takeda wishes to identify therapeutic agents that will benefit from sustained release through depot formulation using microcapsule technology.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with a goal of establishing a Takeda funded collaborative partnership. A finder’s fee of $3,000 will be offered at the Seeker’s sole discretion to submission(s) that provide contacts which meet the criteria of the Challenge.
Source: InnoCentive Challenge ID: 9933674
Challenge Overview
Takeda is well known for its superior depot formulation using microcapsule technology. Controlled sustained release of drugs is achieved using either PLGA (poly-lactic-co-glycolic acid) or PLA (poly-lactic acid) polymer to make microspheres. This core technology is capable of producing injectable formulations that are biodegradable and release drugs over a period of weeks to months. By formulating drugs using this best-in-class approach, Takeda hopes to apply their microcapsule technology to improve the efficacy and safety of known therapeutics compared to the existing administration methods, while providing alternative treatment options to patients with unmet medical needs. In other words, Takeda makes this
[更多]
